PPARG and neoplasm: Instead, PPARγ/RXRα knockdown or pharmacological inhibition restored pro-inflammatory cytokine production, alluding to a tumor-specific role of this NHR warranting the careful choice of agonists vs. antagonists to achieve clinical benefit.